医学
多发性骨髓瘤
硼替佐米
内科学
肿瘤科
德尔菲
重症监护医学
家庭医学
计算机科学
操作系统
作者
Rafaël Fonseca,Adriana Rossi,Rohan Medhekar,Jennifer Voelker,Trevor Homan,Jessica Wilcock,Anna Karakusevic,J.C. Cochrane,Daisy Bridge,Richard Perry,Shuchita Kaila,Faith E. Davies
出处
期刊:Future Oncology
[Future Medicine]
日期:2024-05-20
卷期号:: 1-12
标识
DOI:10.1080/14796694.2024.2342228
摘要
Aim: Obtain clinical consensus on factors impacting first-line prescribing for transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma (NDMM). Materials & methods: A double-blinded, modified Delphi panel was employed. USA-based hematologists/oncologists who treat TIE patients with NDMM were selected as expert panelists. Results: Consensus was reached that patient frailty, performance status, comorbidities, treatment efficacy, and adverse event profile affect first-line prescribing. All panelists agreed it is important to use the most efficacious treatment first; 88% of panelists considered daratumumab-containing regimens the most efficacious. Panelists agreed treatment should be continued until progression while benefits outweigh risk. Conclusion: Findings reinforce the importance of using the most efficacious regimen upfront for TIE NDMM, and nearly all panelists considered daratumumab-containing regimens the most efficacious treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI